tkreiner
From Presage, a Hutch Spinoff, Raises $3M From Angels to Boost Cancer Drug Hit Rate:
Thane Kreiner is CEO of Presage Biosciences.
From Presage, a Hutch Spinoff, Raises $3M From Angels to Boost Cancer Drug Hit Rate:
Thane Kreiner is CEO of Presage Biosciences.
Comments are closed.